PMID- 31090213
OWN - NLM
STAT- MEDLINE
DCOM- 20200806
LR  - 20210109
IS  - 1582-4934 (Electronic)
IS  - 1582-1838 (Print)
IS  - 1582-1838 (Linking)
VI  - 23
IP  - 7
DP  - 2019 Jul
TI  - Use of aspirin in the prevention of colorectal cancer through TIGIT-CD155 
      pathway.
PG  - 4514-4522
LID - 10.1111/jcmm.14332 [doi]
AB  - Colorectal cancer (CRC) is one of the most widespread malignant cancers, with a 
      high incidence and mortality all over the world. Aspirin (ASA) otherwise known as 
      acetylsalicylic acid, is a non-steroidal anti-inflammatory drug that has shown 
      promising results in the prevention of chronic diseases, including several 
      cancers. In previous studies, aspirin has been shown to reduce the incidence of 
      CRC. Immune checkpoint blockade of T cell Ig and ITIM domain receptor (TIGIT) 
      alone or combined with other immune checkpoint blockades moleculars has gained 
      impressive results in the treatment of the melanoma and glioblastoma. Here, we 
      found that TIGIT and Poliovirus receptor (PVR, CD155) are expressed in tumour 
      cells; the TIGIT and CD155 protein expression in cancer tissue has been found to 
      be significantly higher than that in the precancerous tissue. T cell Ig and ITIM 
      domain receptor and CD226 were expressed in the lymphocytes near the tumour 
      tissue and the adjacent tissues. Aspirin has been found to inhibit cancer cell 
      viability and promote CRC cell apoptosis.Similarly, aspirin has also been found 
      to increase pro-apoptotic protein Bax's expression. We found that the expression 
      of TIGIT decreased with an increase in the concentration of aspirin and that the 
      suppression of TIGIT can affect the effect of aspirin on cell proliferation. In 
      this paper, we found that aspirin attenuates cancer cell proliferation and 
      induces CRC cells apoptosis by down-regulating the expression of TIGIT, which 
      provides new evidence for the application of aspirin in cancer treatment.
CI  - (c) 2019 The Authors. Journal of Cellular and Molecular Medicine published by John 
      Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
FAU - Ma, Bin
AU  - Ma B
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
AD  - Department of Oncology Surgery, The First People's Hospital of Yinchuan, 
      Yinchuan, China.
FAU - Duan, Xiangguo
AU  - Duan X
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
AD  - Department of Laboratory Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Zhou, Qiunan
AU  - Zhou Q
AUID- ORCID: 0000-0002-9523-1973
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Liu, Juanxi
AU  - Liu J
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Yang, Xiaojuan
AU  - Yang X
AD  - Department of Laboratory Medicine, College of Clinical Medicine, Ningxia Medical 
      University, Yinchuan, China.
FAU - Zhang, Dong
AU  - Zhang D
AD  - Department of Colorectal Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Yang, Shaoqi
AU  - Yang S
AD  - Department of Gastroenterology, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Du, Yong
AU  - Du Y
AD  - Department of Laboratory Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Li, Hai
AU  - Li H
AD  - Department of Colorectal Surgery, General Hospital of Ningxia Medical University, 
      Yinchuan, China.
FAU - Su, Chunxia
AU  - Su C
AD  - Department of Pathogen Biology and Immunology, School of Basic Medical Science, 
      Ningxia Medical University, Yinchuan, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20190514
PL  - England
TA  - J Cell Mol Med
JT  - Journal of cellular and molecular medicine
JID - 101083777
RN  - 0 (Antigens, Differentiation, T-Lymphocyte)
RN  - 0 (CD226 antigen)
RN  - 0 (Receptors, Immunologic)
RN  - 0 (Receptors, Virus)
RN  - 0 (TIGIT protein, human)
RN  - 0 (bcl-2-Associated X Protein)
RN  - 0 (poliovirus receptor)
RN  - R16CO5Y76E (Aspirin)
SB  - IM
MH  - Antigens, Differentiation, T-Lymphocyte/metabolism
MH  - Apoptosis/drug effects
MH  - Aspirin/pharmacology/*therapeutic use
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Colorectal Neoplasms/*drug therapy/pathology/*prevention & control
MH  - HT29 Cells
MH  - Humans
MH  - Lymphocytes/metabolism
MH  - Receptors, Immunologic/*metabolism
MH  - Receptors, Virus/*metabolism
MH  - *Signal Transduction/drug effects
MH  - bcl-2-Associated X Protein/metabolism
PMC - PMC6584546
OTO - NOTNLM
OT  - CD155
OT  - CD226
OT  - TIGIT
OT  - aspirin
OT  - cell proliferation
OT  - colorectal cancer
COIS- The authors declare no conflict of interest.
EDAT- 2019/05/16 06:00
MHDA- 2020/08/07 06:00
PMCR- 2019/07/01
CRDT- 2019/05/16 06:00
PHST- 2018/11/29 00:00 [received]
PHST- 2019/03/25 00:00 [revised]
PHST- 2019/03/27 00:00 [accepted]
PHST- 2019/05/16 06:00 [pubmed]
PHST- 2020/08/07 06:00 [medline]
PHST- 2019/05/16 06:00 [entrez]
PHST- 2019/07/01 00:00 [pmc-release]
AID - JCMM14332 [pii]
AID - 10.1111/jcmm.14332 [doi]
PST - ppublish
SO  - J Cell Mol Med. 2019 Jul;23(7):4514-4522. doi: 10.1111/jcmm.14332. Epub 2019 May 
      14.